top of page

Price

chg

chg neg

quotes and stock data may be delayed 15 minutes

 My Notes

Only BPIQ Pro members can create company notes. Learn more here.

52 wk low

low api

52 wk hi

high api

Cash

$73.0M

Burn Rate (Qtr)

$15.7M

Mkt Cap

mkt cap api

Avg Volume

volume api

*cash/burn updated:

Q1 '22

Drug Pipeline

Click the button to see the updated pipeline

No drug found

We don't have any drug data for this company yet

Drug | Disease (links)

Stage (next event)

Catalyst Date

Drug Name

Indication

Phase

Event

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Loading Catalysts...

search in progress

Pipeline powered by

ANGN

BPIQ_Logo_RGB-01.jpg

Company Profile

Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company’s lead product candidate is ANG-3777, a hepatocyte growth factor mimetic for acute kidney injury, acute lung injury, acute respiratory distress syndrome, central nervous system injuries, and heart injuries. It also develops products, such as ANG-3070 tyrosine kinase inhibitor and rho kinase 2 inhibitors for fibrotic diseases; and CYP11B2, an aldosterone synthase inhibitor for aldosterone-related fibrotic diseases. The company was incorporated in 1998 and is based in Uniondale, New York with additional offices in San Francisco, California and Newton, Massachusetts.

Recent Posts

See what the community is saying - click to see full post.

Smid-cap Biopahrma M&A activity - Q1 '23 Biggest Quarter in Years!

Smid-cap Biopahrma M&A activity - Q1 '23 Biggest Quarter in Years!

December 2021 Big-Mover™ Stocks and Movers to Watch Report

ASN Kidney Week Presenters - Updated

October 2021 Big-Mover™ Stocks to Watch and Movers to Watch List

bottom of page